Mounjaro®
Starting from £179.99/mo
Start journey Learn moreBody aches are a recognised side effect of Mounjaro (tirzepatide). They most commonly appear in the first days after a new injection or a dose step-up, tend to be mild to moderate, and usually settle within a few days without any treatment. They are not a sign that something has gone seriously wrong, though there are specific symptoms that should prompt prompt medical attention. As a prescription-only medicine, Mounjaro is prescribed only after a clinical assessment determines it is suitable for you, and any persistent or worsening muscle or joint pain should always be discussed with your prescribing team.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
You have given yourself your weekly Mounjaro injection, and by the following morning your legs feel heavy and your back has a dull, diffuse ache you cannot quite place. This is a pattern our prescribers hear described regularly, and it fits what the pharmacology would predict. Tirzepatide activates both GIP and GLP-1 receptors, slowing the gut and shifting the body's energy handling. The adjustment is real and physical, and for some people it shows up as generalised achiness rather than (or alongside) the more familiar nausea.
The NHS medicines page for tirzepatide lists musculoskeletal pain and back pain among the side effects that some people experience. These are distinct from the gastrointestinal effects that get most of the attention; some people have minimal nausea but notice muscular discomfort instead. The aches are not the same as the injection-site reactions (redness or tenderness at the spot itself), which are also possible but locally confined.
Timing matters here. Most people find that body aches on Mounjaro follow their injection day fairly closely, peaking in the first one to three days and fading before the next dose is due. If the aches arrive on roughly the same schedule every week and then resolve, that regularity is itself informative. It suggests your body is responding to the weekly pharmacological shift rather than something unrelated. Our page on whether Mounjaro gives body aches goes into more detail on why this pattern occurs and what most people experience across their treatment. That pattern, logged over two or three cycles, is exactly what a prescriber needs to help you.
Generalised muscular heaviness, mild joint stiffness and the kind of tired-body sensation you might associate with a mild flu are generally within the expected range, particularly in the first few weeks of treatment or after a dose increase. They are uncomfortable, but they do not typically indicate harm. Paracetamol taken at the standard adult dose can help, and gentle movement (a short walk, some stretching) often does more good than resting rigidly in one position.
There are, however, symptoms that sit in a different category. Severe abdominal pain that radiates through to the back, particularly if accompanied by vomiting, is not post-injection muscle achiness. The MHRA specifically highlighted acute pancreatitis as a known but uncommon risk with GLP-1 medicines in a January 2026 Drug Safety Update. You can report any suspected serious reaction directly via the MHRA's Yellow Card scheme. Gallbladder pain (typically sharp discomfort in the upper right abdomen) also requires prompt assessment. These are not reasons to panic; they are reasons to act quickly. If you are in any doubt about whether what you are feeling is ordinary muscle soreness or something more, contacting 111 or your GP is the right call.
The distinction that helps most people is this: does the pain feel diffuse, across muscles, and loosely timed to your injection? Or is it sharp, localised, abdominal, and unlike anything you have felt before? The former is probably the adjustment effect the trials documented. The latter warrants urgent attention.
If body aches after Mounjaro settled after your first few weeks and then reappeared, the most likely explanation is a dose step-up. Titration (moving from 2.5 mg to 5 mg, for example, or to a higher strength) restarts the adjustment process. The body has adapted to one pharmacological level; a higher dose presents a new challenge, and the muscular and systemic side effects can briefly resurface.
This is expected rather than alarming. The prescriber who oversees your treatment at a service like ours at nume reviews your response before any dose change, which is part of why evidence of how you are tolerating your current dose matters. If the aches from a previous step-up took two weeks to settle, that is useful context for deciding the pace of the next increase. Slower titration is sometimes the right call for people whose bodies react more noticeably.
You can read more about how tirzepatide works and what the wider clinical programme showed in our tirzepatide overview. For a broader look at Mounjaro in the UK, including eligibility and how to get started, that page covers the full picture. People wondering specifically about muscle aches on Mounjaro will find a more detailed breakdown of that particular symptom there.
A few things tend to help. Staying well hydrated is consistently underestimated: GLP-1 medicines reduce appetite and thirst cues together, and mild dehydration makes any muscular discomfort meaningfully worse. Aiming for six to eight glasses of water on injection days and the day after is a low-effort habit with real payoff.
Protein intake is worth monitoring too. When appetite drops significantly, some people inadvertently eat too little protein, which affects how muscles feel and recover. This is worth raising with your prescriber or a dietitian if it becomes a pattern.
If the aches are severe enough to interfere with sleep or daily activity, or if they do not ease within a week, tell your clinical team. At nume, our prescribers review every repeat order before it is issued, which means there is a natural checkpoint at every cycle. If you want to raise a specific concern between orders, our support team can connect you with the prescribing team directly.
People researching what others experience often ask whether the aches improve over time. In general, they do. For most people on Mounjaro, the body-ache pattern is most prominent in the first month and with each dose increase, then becomes progressively less noticeable as the body settles. That is not guaranteed for everyone, but it is the common trajectory that our prescribers see reflected in their patients' accounts.
If you are considering starting treatment and want to discuss your individual circumstances, including any musculoskeletal conditions that might affect how you tolerate tirzepatide, a free consultation through our treatment page connects you with a GPhC-registered prescriber who can give you a considered answer. Patients based in Northern Ireland can find location-specific information, including how to access treatment locally, on our Mounjaro Belfast page. For context on what private treatment involves in terms of cost, our Mounjaro price comparison guide lays that out plainly.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.